---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095175"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:37.421486+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS

## Summary
- Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.
- SPOTLIGHT study: 93% clinical response (83% complete response) in 120mg cohort; no SAEs.
- Initial BEACON data in CSU expected week of Jan 6, 2025; asthma challenge study cleared in Canada/EU.
- Discontinued LR-MDS program as briquilimab did not improve hematopoiesis.
- R&D expenses $14.5M, G&A $5.4M for Q3 2024.

## SEC filing metadata
- accession: 0001213900-24-095175
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390024095175/0001213900-24-095175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390024095175/ea0220162-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095175
- JSON: https://secwatch.observer/filing/0001213900-24-095175.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.